Carregant...
Effectiveness of EGFR‐TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR‐RAD51 Fusion
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR‐TKIs) have become the first choice for patients with sensitive mutations and have significantly improved prognosis. EGFR exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarci...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693705/ https://ncbi.nlm.nih.gov/pubmed/31064887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0732 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|